Amgen and Boehringer Ingelheim have signed an agreement under which Boehringer will acquire the rights to, and the assets of, Amgen's Fremont CA development and manufacturing facility. The 100,000-sq.-ft. manufacturing facility currently has approximately 360 employees and includes a pilot plant and process development labs. The transaction is expected to close in March.
“With great enthusiasm, we look forward to welcoming the Amgen Fremont employees into the Boehringer Ingelheim family of companies,” said Prof. Dr. Wolfram Carius, Boehringer Ingelheim board of managing directors. “The technological expertise at Fremont and the state-of-the-art facility will enable us to further strengthen our global Contract Manufacturing Business including new biological entity process development and manufacturing efforts. We greatly value our relationship with Amgen and are enthusiastic about joining the San Francisco Bay Area biotechnology community and for the opportunity to better serve our current and future contract manufacturing customers.”
“We are pleased to be able to build upon a successful contract manufacturing relationship with Boehringer Ingelheim,” said Dr. Fabrizio Bonanni, Amgen executive vice president of operations. “We look forward to continuing to work closely with them to support Amgen's delivery of safe and effective medicines to patients around the world.”